InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,288.80
(
-0.62%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.85
(
-0.19%
)
Bitcoin
64,545.70
(
-0.42%
)
Post# of 252279
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 132004

Tuesday, 11/29/2011 4:29:56 PM

Tuesday, November 29, 2011 4:29:56 PM

Post# of 252279

the FDA reviewers think Eliquis has something to offer in this indication beyond what Pradaxa and Xarelto can. The data for Eliquis in warfarin-intolerant patients provides such a justification

Also, Eliquis is the only one that showed stat-sig reduction in all cause mortality compared to warfarin (in ARISTOTLE trial). Pradaxa and Xarelto were both approved with non inferiority and given Eliquis data it should get superiority clam vs warfarin in its AFib label.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up